Searched for
LUPIN DIABETES DRUGS
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Lupin launches generic anti-diabetic tablets in USPharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...
- GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy genericsIndian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...
- Lupin shares in focus on acquisition of 3 anti-diabetes trademarks to strengthen diabetes portfolioLupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...
- Boehringer Ingelheim India and Lupin enter agreement to market diabetes drugIMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.
- Lupin launches generic diabetes drug in the USLupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF product...
- Japanese company loses patent bid for diabetes drugThe Kolkata Patent Office, on an opposition filed by domestic drug firm Lupin, refused the patent application on grounds that it was "obvio...
- Lupin, Boehringer Ingelheim to co-market anti-diabetes drug linagliptin in IndiaBoehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...
- Lupin inks pact with South Korean firm to launch diabetes drugAs per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine.
- Lupin gets USFDA approval for diabetes management drug"Lupin's Pioglitazone tablets is to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings," the co...
- Lupin gets USFDA nod for diabetes drugLupin has received US health regulator's approval to sell its generic version of Glumetza HCl ER Tablets in US market.
- Diabetes drug ban to help companies like USV, Sun Pharma, LupinIn the wake of a government ban on top-selling diabetes drug, pioglitazone , the volumes are expected to shift to other classes such as fir...
- Lupin settles patent dispute with US firms over diabetes drugLupin today said it has reached a patent litigation settlement agreement with US-based firms Santarus Inc and Depomed Inc involving diabete...
- Lupin gets USFDA approval for diabetes drugLupin today said it has received approval from the US health regulator for its Metformin Hydrochloride Extended Release tablets, used in tr...
- Novo sues Lupin to block generic in USDanish company Novo Nordisk has sued Mumbai-based drugmaker Lupin to prevent it from launching the low priced version of its patented diabe...
- Lupin to diversify into therapeutic segmentsAntibiotics and speciality domestic pharma major Lupin is planning to diversify into new therapeutic segments.
Load More
